For now, there is no need to replace ACE inhibitors or AT1R blockers with other drugs (during the treatment of arterial hypertension) during the COVID-19 pandemic for fear of a higher risk of SARS-CoV-2 infection and a more life-threatening course of the disease. The gene discussed is ACE; the disease is Hypertension.